Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals is a clinical-stage pharmaceutical company developing therapies for endocrine conditions and neurodegenerative diseases. Its lead investigational asset, avexitide, is being evaluated for post-bariatric hypoglycemia and congenital hyperinsulinism. Other programs include AMX0035, an oral fixed-dose combination of sodium phenylbutyrate and taurursodiol being investigated for Wolfram syndrome; AMX0114, an antisense oligonucleotide targeting calpain-2 in ALS; and AMX0318, a GLP-1 receptor antagonist selected for development in post-bariatric hypoglycemia and other rare diseases. Amylyx earns no commercial product income described here; it is focused on research and clinical development, with its drug candidates supplied for clinical trials through third-party contract manufacturers. The company is headquartered in Cambridge, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $AMLX in the last 30 days.
See all $AMLX insider activity →Stifel maintains a Buy rating and $45.00 price target on Amylyx Pharmaceuticals (AMLX), citing positive data and potential revenue. The stock is up 143% YTD, with a market cap of $3.69B. Amylyx plans to present LUCIDITY data and expects an IND application in 2027. Q3 2026 earnings met expectations, with a loss of $0.38 per share.
Amylyx Pharmaceuticals reported no product revenue in Q3 2026, with a net loss of $45.49M, up 32.3% YoY. Higher R&D costs were partially offset by increased interest income. Avexitide's Phase 3 trial met its primary endpoint, and the company plans an NDA submission by year-end 2026. AMX0114 and AMX0318 are in early stages of development.
Amylyx Pharmaceuticals, Inc. (AMLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results • Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track • Results
Over the past 7 days, AlphAI's AI scored 7 news stories mentioning AMLX (Amylyx Pharmaceuticals, Inc.). Coverage has skewed bullish: 3 bullish, 3 neutral, and 1 bearish.
Recent AMLX coverage spans financial news, earnings and market movers.
Analyst upgrade with higher price target may support modest upside.
Earnings miss with higher loss likely pressures the stock.
Positive trial data and strong cash position may boost sentiment.
The announcement may generate modest buying interest ahead of the data release, but impact is limited until trial results are disclosed.
The earnings announcement date may trigger pre‑earnings positioning and post‑release volatility.
AlphAI scores every news story that mentions AMLX with an AI model for sentiment and relevance, and aggregates insider trades from Amylyx Pharmaceuticals, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Stifel maintains a Buy rating and $45.00 price target on Amylyx Pharmaceuticals (AMLX), citing positive data and potential revenue. The stock is up 143% YTD, with a market cap of $3.69B. Amylyx plans to present LUCIDITY data and expects an IND application in 2027. Q3 2026 earnings met expectations, with a loss of $0.38 per share.
Amylyx Pharmaceuticals reported no product revenue in Q3 2026, with a net loss of $45.49M, up 32.3% YoY. Higher R&D costs were partially offset by increased interest income. Avexitide's Phase 3 trial met its primary endpoint, and the company plans an NDA submission by year-end 2026. AMX0114 and AMX0318 are in early stages of development.
Amylyx Pharmaceuticals, Inc. (AMLX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Amylyx Pharmaceuticals Reports Third Quarter 2026 Financial Results • Reported positive topline results from Phase 3 LUCIDITY clinical trial of avexitide in post-bariatric hypoglycemia; New Drug Application submission planned by end of 2026 remains on track • Results
Amylyx Pharmaceuticals (AMLX) will host an investor event on Nov. 15, 2026, to discuss Phase 3 LUCIDITY trial results for avexitide, a treatment for post-bariatric hypoglycemia (PBH). The event will feature KOLs and management, with a webcast available. Avexitide has Breakthrough Therapy and Orphan Drug Designations from the FDA for PBH and congenital hyperinsulinism.
Amylyx Pharmaceuticals (AMLX) will release its Q3 2026 financial results on November 5, 2026, followed by a conference call and webcast at 8:00 a.m. ET. The call will discuss financial performance and company updates. Access details and a replay will be available on the company's investor relations website.
Amylyx Pharmaceuticals (AMLX) shares fell due to profit-taking and dilution concerns from a $500M offering, despite a raised price target of $43. The company has positive Phase 3 data for avexitide, a cash runway into 2028, but faces risks from high cash burn and regulatory uncertainties.
Amylyx Pharmaceuticals' average stock price target increased from $42.36 to $43, according to 11 analysts, with a range of $20 to $57. This implies 59% upside from the Oct. 14 closing price. The consensus rating remains 'Buy' among 12 analysts.
MILNE GEORGE M JR sold 30,000 shares of Amylyx Pharmaceuticals, Inc. (AMLX) at $27.70 ($0.83M total) on 2026-10-05 under a Rule 10b5-1 trading plan.
Amylyx Pharmaceuticals, Inc. has a lock-up agreement for certain restricted stock units ending on 4-OCT-2026. The company, its officers, and directors agreed not to dispose of or hedge shares for 45 days post-prospectus supplement, except with consent from Leerink Partners, Morgan Stanley, and Guggenheim Securities. Amylyx focuses on investigational therapies, including avexitide for hypoglycemia and AMX0035 for neurodegeneration.
Amylyx Pharmaceuticals reported positive Phase III results for avexitide in treating PBH, with plans to file for FDA approval by year-end. The company estimates 160,000 U.S. patients with PBH, with 120,000 following Roux-en-Y gastric bypass. Management is preparing for a potential 2024 or 2027 launch, depending on the FDA label. Amylyx is also developing AMX0318 for PBH, targeting an IND filing next year.
